Funding Acknowledgements Type of funding sources: None. Background Less evidence is available regarding clinical, angiographic characteristics and outcomes of patients with non-ST elevation acute coronary syndrome (ACS) with metabolic syndrome (MS). Purpose We aimed to assess the clinical, angiographic characteristics and short-term outcomes of patients admitted to our hospital with non-ST elevation ACS with MS. Methods 128 patients with non-ST elevation ACS were enrolled in the study (Aged 38-75 years; mean age 56.2±16.85 years; male 53%). Patients were divided into two groups according to concomitant metabolic syndrome. Group I consisted of 64 patients with MS and Group II (n=64) without MS. Anthropometric, laboratory and instrumental data were assessed at baseline together with clinical and angiographic characteristics. All statistical analysis were done with STATA software. Results Non-ST elevation ACS patients with MS (Group I) tended to be younger (52.5 vs. 58.6, P<0.05), female gender (57% vs. 46%, P<0.05), smoked less (21.0 vs. 28.2%, P<0.05), having greater BMI (30.4 vs 26.8, P<0.05), having less pronounced symptoms (P<0.05) and greater extensive lesions in coronary angiography (P<0.05) than those without MS. There were similar single-vessel (52% vs. 55%, P>0.05) and multi-vessel (28% vs 26%, P>0.05) lesions in both groups in coronary angiography. New revascularization was higher in Group I than Group II (72% vs. 65%, P<0.05). In 12% of patients non-ST elevation ACS was occurred due to vasospasm in Group I and in 11% in Group II. There were similar hospitalization days in both groups (P>0.05), however short-term outcomes was better in Group II in 6 months (P<0.05). Conclusion MS is associated with higher rate of revascularization and worse outcome in patients presenting non-ST elevation ACS.

Funding Acknowledgements Type of funding sources: None. Background Covid-19 was emerged in Wuhan and disseminated to the rest of the world. The virus may affect any kind of human organs. Aim of the study was to estimate the blood D-dimer level after Covid-19 in patients with coronary heart disease. Methods 65 patients who were undergone Covid-19 (mild to moderate severity) without coronary heart disease (CHD; Group 1; aged 42-76 years, mean age 56.8±13.5 years) and 65 patients with CHD who was affected with Covid-19 (Group 2; aged 45-72 years, mean age 57.4±12.8 years) have been enrolled in this prospective study. Baseline characteristics were collected when first admitted to the hospital due to Covid-19, and follow-up characteristics were collected when they admitted to our hospital for the rehabilitation after undergoing Covid-19 in 3 months. Baseline and follow-up anthropometric, laboratory and instrumental data were assessed. All statistical analysis were performed by STATA software. Results Mean blood D-dimer level significantly reduced in both groups (from 864 ng/mL to 475 ng/mL in the first group, P<0.05 vs. from 812 ng/mL to 452 ng/mL in the Group 2, P<0.05), however there were not observed statistically significant changes when compared to groups, P>0.05. In the first group mean D-dimer level tended to be higher in men, with high fibrinogen level, and older patients. In the second group, D-dimer level tended to be higher in patients with higher body mass index (BMI) with high fibrinogen level. In the first group in 31% of patients was observed high level of D-dimer (>500 ng/mL) after 3 months whereas in the second group elevated D-dimer level maintained in 28% of patients. Conclusion Elevated blood D-dimer level are common after Covid-19, however concomitant CHD does not effect on it. Further studies are needed to reveal mechanisms of it.

Funding Acknowledgements Type of funding sources: None. Background Even though, bilirubin is known to be an endogenous antioxidant, there is conflicting evidence whether level of serum bilirubin is associated with non-ST elevation acute coronary syndrome (NSTE ACS). Purpose We aimed to assess the possible impact of bilirubin level non-ST elevation acute coronary syndrome. Methods 128 patients with NSTEACS were enrolled in the study (Aged 38-75 years; mean age 56.2±16.85 years; male 53%). Patients were divided into two groups in terms of level of total bilirubin. Group I included 56 patients (total bilirubin was higher 19 mMol/L) and Group II 72 patients with NSTA ACS (total bilirubin was lower 19 mMol/L). Anthropometric, laboratory including serum total, direct, indirect bilirubin level and instrumental data were obtained at baseline while admission prior to percutaneous coronary intervention. Follow-up was conducted via telephone in six months. Statistical analysis were performed by STATA software. Results Patients presenting with NSTE ACS having high level of bilirubin tended to have more severe course of the disease (62% vs. 53%, P<0.05), high level of high sensitive troponin level (55ng/mL vs. 43 ng/mLK, P=0.001), multi-vessel disease (35% vs. 21%, P=0.001) and high rate of new revascularization (82% vs. 65%, P=0.001) than those ones with lower level of total bilirubin. Patients with high level of total bilirubin at admission with NSTE ACS had worse outcomes both in 1 month (1.24; 1.12-1.75; CI 95%; P<0.05) and 6 months follow-up period than those NSTE ACS patients with lower bilirubin level at admission (1.512; 1.24-1.95; CI 95%; P<0.05). Conclusion Total serum bilirubin level seems to be an independent predictor for severity of the disease and adverse outcomes in patients with NSTE ACS.

No abstract

To study effect of сomplex therapy and nebivololi on parameters of ventilationperfusion function of lang and parameters of diastolic function right ventricle of heard in patients with bronchial asthma complicated by pulmonale hypertension failure.